"Et tu, Brute?" - A Case of Ixazomib - Induced Cancer Therapy-related Cardiac Dysfunction

Abstract

An 81-year-old man with a history of multiple myeloma presented with decompensated heart failure (HF). Although his baseline left ventricular ejection fraction (LVEF) was preserved, it significantly declined to 35% at 13 months after the initiation of ixazomib. Considering the chronological relationship between the timing of ixazomib treatment and symptom onset, prior normal echocardiography, and multimodal imaging findings, ixazomib-induced cancer therapy-related cardiac dysfunction (CTRCD) was strongly suspected. Despite the discontinuation of ixazomib and continued administration of guideline-directed medical therapy, his LVEF has not recovered to date. We herein report a rare case of ixazomib-induced irreversible CTRCD.

Early Cardiac Biomarkers for the Detection of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer: A Systematic Review and Meta-Analysis
Nazym Askambayeva, Zhuldyz Myrzabay, Ahmad J. Harahsheh +3
Journal of Clinical Medicine1 Oct 2026Peer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMC
Cardiovascular Magnetic Resonance for Early Detection of Cancer Therapy-Related Cardiac Dysfunction: From Multiparametric Tissue Signatures to Clinical Pathways
Qikai Zong, Cheng Sun, Tianxiang Gu +2
Cancers16 Oct 2026Peer-reviewedCC BY 4.0Cardiovascular medicineCrossref
Early Lymphocyte Dynamics and Subsequent Cancer Therapy-Related Cardiac Dysfunction in Patients Receiving Anthracycline Therapy
S. Zhang, L. Dao, Y. Pang +4
medRxiv26 Oct 2026PreprintCC BY-NC-NDFull textCardiovascular medicinemedRxiv
TRPM4-related left bundle branch block-induced cardiomyopathy reversed by left bundle branch area pacing-based cardiac resynchronization therapy: a case report.
Sijin Wu, Xinyue Wang, Bin Zhou +2
European heart journal. Case reports21 Sep 2026Peer-reviewedCC BY-NCFull textCardiovascular medicineEurope PMC
Integrated hs-cTnI, global longitudinal strain, and coronary artery calcium for risk stratification of anthracycline-related cardiac dysfunction in multiple myeloma
Xueshan Zhang, Zongliang Yu
Frontiers in Cardiovascular Medicine8 Oct 2026Peer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMC

Cite

BibTeX RIS

BibTeX

@article{hirao2026brute,
  title = {{"Et tu, Brute?" - A Case of Ixazomib - Induced Cancer Therapy-related Cardiac Dysfunction}},
  author = {Yusuke Hirao and Kensuke Matsumoto and Yu Mizutani and Shinnosuke Tsukamoto and Akari Odagi and Yuto Shinkura and Ryo Nishio and Masahiko Hoshijima and Satoru Kawasaki and Hogara Nishisaki},
  journal = {Internal Medicine},
  year = {2026},
  month = oct,
  doi = {10.2169/internalmedicine.6894-25},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/19/65_6894-25/_article},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - "Et tu, Brute?" - A Case of Ixazomib - Induced Cancer Therapy-related Cardiac Dysfunction
AU  - Yusuke Hirao
AU  - Kensuke Matsumoto
AU  - Yu Mizutani
AU  - Shinnosuke Tsukamoto
AU  - Akari Odagi
AU  - Yuto Shinkura
AU  - Ryo Nishio
AU  - Masahiko Hoshijima
AU  - Satoru Kawasaki
AU  - Hogara Nishisaki
PY  - 2026
DA  - 2026/10/01
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.6894-25
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/65/19/65_6894-25/_article
AB  - An 81-year-old man with a history of multiple myeloma presented with decompensated heart failure (HF). Although his baseline left ventricular ejection fraction (LVEF) was preserved, it significantly declined to 35% at 13 months after the initiation of ixazomib. Considering the chronological relationship between the timing of ixazomib treatment and symptom onset, prior normal echocardiography, and multimodal imaging findings, ixazomib-induced cancer therapy-related cardiac dysfunction (CTRCD) was strongly suspected. Despite the discontinuation of ixazomib and continued administration of guideline-directed medical therapy, his LVEF has not recovered to date. We herein report a rare case of ixazomib-induced irreversible CTRCD.
SN  - 1349-7235
SN  - 0918-2918
ER  -

Abstract

Related

Cite